Shares of Hims & Hers Health experienced a significant rally on Monday, climbing 8.9% by mid-morning trading. This advance extends an impressive weekly gain of 48.3% as investors position themselves ahead of the company's upcoming earnings release scheduled for May 11. The broader telehealth sector remained in focus, though performance was mixed with peers like Privia Health and Omnicell posting gains of less than 1% during the same session.
Healthcare Tech Performance Diverges
The recent movement in healthcare technology stocks highlights a notable divergence within the sector. While the group has not shown widespread weakness, recent analyses present contrasting views on specific companies. According to sector roundups, most healthcare technology firms surpassed fourth-quarter revenue expectations. One analysis indicated that a subset of four companies focused on hospital and clinic services exceeded revenue estimates by an average of 1.8%. A broader Friday report identified seven healthcare-tech firms that beat estimates, specifically highlighting Hims & Hers and Privia Health for standout performance.
Hims & Hers Posts Strong Growth Metrics
Hims & Hers reported robust financial results for the fourth quarter of 2025. Revenue reached $617.8 million, representing a 28% increase compared to the same period the previous year. The company concluded the year with a subscriber base of 2.511 million. Looking forward, management has provided 2026 revenue guidance in the range of $2.7 billion to $2.9 billion. Chief Executive Andrew Dudum confirmed the subscriber count has surpassed 2.5 million.
FDA Review Provides Key Catalyst
A primary driver behind the recent stock appreciation is a scheduled U.S. Food and Drug Administration meeting. The regulator will convene on July 23-24 to evaluate whether compounding pharmacies should receive authorization to produce certain peptides. These short amino acid chains are often marketed for conditions including obesity, wound healing, and insomnia. This regulatory development is particularly significant for Hims & Hers, which acquired a peptide manufacturing facility in California last year.
Analysts have reacted positively to this development. Michael Cherny of Leerink described the FDA's move as a "clear positive for Hims." Allen Lutz of Bank of America pointed to the "optionality around new potential revenue streams." The company's Chief Medical Officer, Pat Carroll, stated that Hims & Hers is "actively exploring ways to expand access to peptides" and intends to comply fully with forthcoming FDA guidance.
Challenges and Cautions Remain
Despite the optimistic momentum, challenges persist for the telehealth provider. In February, the company issued first-quarter revenue guidance between $600 million and $625 million, which fell short of analyst expectations. Management attributed this forecast to a projected $65 million headwind related to new shipping regulations for its personalized weight-loss products. Analyst commentary suggests the market will closely monitor how the company executes within the competitive weight-loss segment moving forward.
Omnicell Reports Mixed Quarterly Results
In contrast to Hims & Hers, Omnicell found itself on the weaker end of recent performance. A recent sector review labeled it the poorest fourth-quarter performer among technology vendors serving hospitals and clinics. The company is scheduled to report its first-quarter earnings on April 28.
Omnicell's fourth-quarter financials presented a mixed picture. Revenue came in at $314 million, marking a modest 2% year-over-year increase. However, the company posted a GAAP net loss of $2 million. Non-GAAP earnings were $0.40 per share, a decline from the $0.60 per share reported a year earlier. A positive note was the growth in annual recurring revenue, which climbed to $635.6 million. Conversely, product bookings for 2025 decreased by 4%, indicating uneven business momentum. CEO Randall Lipps characterized the period as delivering "solid fourth quarter financial results."
Privia Health Outperforms
Privia Health delivered a more consistently positive report. Fourth-quarter revenue increased 17.4% to $541.2 million. The company stated that all operating and financial metrics for 2025 met or exceeded the top end of its guidance ranges. For the 2026 fiscal year, Privia established a revenue outlook between $2.35 billion and $2.45 billion. Its next earnings report is due on May 7.
The disparity in performance underscores the selective nature of the current market, where company-specific catalysts and execution are driving significant valuation gaps within the healthcare technology landscape.
